홈 > 시장보고서 > 의약품

시장보고서

상품코드

1290353

세계의 화학요법 유발성 빈혈 시장(2023-2030년)

Global Chemotherapy-Induced Anemia Market - 2023-2030

발행일: 2023년 06월 | 리서치사:

DataM Intelligence | 페이지 정보: 영문 195 Pages | 배송안내 : 1-2일 (영업일 기준)

■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

시장 개요

세계의 화학요법 유발성 빈혈 시장 규모는 2022년 22억 4,000만 달러에 달하며, 2030년에는 38억 9,350만 달러에 달할 것으로 예상됩니다. 화학요법 유발성 빈혈 시장은 예측 기간(2023-2030년) 동안 7.2%의 CAGR을 보일 것으로 예상됩니다.

빈혈은 체내 적혈구의 상태가 정상보다 낮은 상태를 말합니다. 적혈구가 부족하면 신체 각 부위에 충분한 산소가 공급되지 않습니다. 그 결과 신체 각 부위가 필요한 기능을 수행하지 못해 문제가 발생합니다. 체내에서 충분한 적혈구가 만들어지지 않거나 적혈구가 빠져나가면 빈혈이 발생합니다. 또한 혈류에서 많은 혈액을 잃으면 빈혈을 유발할 수 있습니다. 빈혈은 암과 암 치료로 인한 전형적인 부작용이며, 특히 화학요법을 받는 사람들에게서 두드러집니다.

시장 역학

암 환자 증가는 예측 기간 중 세계 화학요법 유발성 빈혈 시장을 주도하고 있습니다.
암 사례 증가는 예측 기간 중 세계 화학요법 유발성 빈혈 시장을 주도하고 있습니다. 예를 들어 GLOBOCAN 2020에 등록된 2022년세계에서 발표된 연구에 따르면 평가된 1,930 만 건의 사례와 1,000 만 건 이상의 사망이 암으로 인한 것으로 나타났습니다. 전체 환자 중 세계에서 일반적으로 발견되는 암 발생률은 여성 전립선암(141만 명, 7.3%), 폐암(221만 명, 11.4%), 유방암(226만 건, 11.7%) 순이었습니다.

고령화 인구는 세계 화학요법 유발성 빈혈 시장에 긍정적인 성장 기회를 제공하고 있습니다.

암은 나이에 관계없이 성장할 수 있지만, 나이가 들어감에 따라 많은 유형의 암이 더 흔해집니다. 이는 나이가 들어감에 따라 신체 세포가 손상되기 때문입니다. 이러한 노화가 나이가 들면서 진행되어 암을 유발할 수 있는 것입니다. 이처럼 노인 인구 증가는 향후 몇 년동안 세계 시장에 유망한 성장 기회를 가져올 것입니다. 예를 들어 유엔의 'World Population Prospects 2022'에 따르면 80세 이상 인구는 2022년 1억 5700만 명에서 2050년 4억 5900만 명으로 3배 증가할 것으로 예상됩니다.

COVID-19의 영향 분석

COVID-19 분석에는 Pre-COVID 시나리오, COVID 시나리오, Post-COVID 시나리오가 포함되며, 가격 역학(팬데믹 기간 및 팬데믹 이후 가격 변동과 COVID 이전 시나리오와의 비교), 수급 스펙트럼(거래 제한, 봉쇄 및 이후 공급과 수요의 변화), 정부의 구상(정부 기관 시장, 부문, 산업 활성화 방안), 제조업체의 전략적 노력(제조업체의 COVID 문제 완화 노력)에 대해서도 설명할 예정입니다.

러시아·우크라이나 분쟁의 영향 분석

우크라이나의 전쟁으로 인해 수백만 명의 사람들이 무질서한 삶을 살면서 많은 우크라이나 사람들이 국가의 서부 지역으로 탈출해야 했고, 유럽과 해외로 난민으로 떠나야 했습니다. 그 중에는 암 환자들도 포함되어 있으며, 극심한 질병과 망명이라는 극한의 일촉즉발의 상황에 처해 있습니다. 또한 우크라이나의 암 전문 병원이 습격당하는 등 한산한 가운데 국경을 넘은 우크라이나 환자들은 제재와 인플레이션에 시달리며 치료의 미래조차 불투명한 상황에 처해 있습니다.

세계적 불황의 영향 분석

헬스케어 산업이 불황과 전혀 무관한 것은 아닙니다. 하지만 그 본질적인 특성으로 인해 다른 산업보다 더 잘 구상하고 있습니다. 그러나 인플레이션이 계속 상승하면서 경기 침체 위기가 시장을 위협하고 있습니다. 세계 선진국의 고인플레이션은 지난 2년 동안 일반적인 비용 상승으로 이어져 경기 침체 지속에 대한 긴장감을 높이고 있습니다. 일반적인 구매 의욕의 누적된 악화는 특히 성장 경제에 영향을 미칠 것으로 예상되며, 여러 가지 측면에서 유익할 것으로 보입니다.

Market Overview

The Global Chemotherapy-Induced Anemia Market size reached USD 2,240 million in 2022 and is projected to witness lucrative growth by reaching up to USD 3,893.5 million by 2030. The chemotherapy-induced anemia market is expected to exhibit a cagr of 7.2% during the forecast period (2023-2030).

Anemia is a condition in which the body's status of red blood cells goes below normal. When the body does not contain adequate RBCs, the body parts do not acquire sufficient oxygen. As a consequence, they cannot perform in the manner they require to and induce issues. Individuals conceive anemia if their body does not produce adequate RBCs or eliminates them. Thus, individuals can even induce anemia if they lose too much blood from their bloodstream. Anemia is a typical side consequence of cancer and cancer therapy, specifically true for individuals accepting chemotherapy.

Market Dynamics

The Growing Cases Of Cancer Are Driving The Global Chemotherapy-Induced Anemia Market In The Forecast Period.

The growing cases of cancer are driving the global chemotherapy-induced anemia market during the forecast period. For instance, according to a research study published in 2022 worldwide, an assessed 19.3 million cases and over 10 million demises were because of cancer as registered in GLOBOCAN 2020. Among these entire patients, the incidence of typically detected cancers globally were female prostate cancers (1.41 million, 7.3%), lung (2.21 million, 11.4%), and breast (2.26 million cases, 11.7%).

The Geriatric Population Is Providing The Global Chemotherapy-Induced Anemia Market With Prospective Growth Opportunities.

Cancer can grow at any age, despite as individuals get older, a majority of kinds of cancer become more typical. This is because the body's cells can get harmed over the period. This deterioration can then produce up as individual ages, and can frequently yield cancer. Thus, the growing geriatric population presents the global market with prospective growth opportunities in the upcoming years. For instance, according to the World Population Prospects 2022, from the UN, the number of individuals aged 80 or above is anticipated to grow triple fold, from 157 million in 2022 to 459 million by 2050.

COVID-19 Impact Analysis

The COVID-19 analysis includes Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario along with pricing dynamics (including pricing change during and post-pandemic comparing it to pre-COVID scenarios), demand-supply spectrum (shift in demand and supply owing to trading restrictions, lockdown, and subsequent issues), government initiatives (initiatives to revive market, sector or industry by government bodies) and manufacturers strategic initiatives (what manufacturers did to mitigate the COVID issues will be covered here).

Russia-Ukraine War Impact Analysis

As the warfare in Ukraine released disorder and uprooted millions of individuals, numerous Ukrainians had to escape to the western region of the nation and became refugees in Europe and outside. Among them were individuals with cancer, who encountered a fierce one-two force of extreme sickness and exile. And while cancer hospitals in Ukraine are being deserted or even attacked, Ukrainian patients across the boundary, struck by sanctions and inflation, even encounter an indefinite future for their care.

Global Recession Impact Analysis

The healthcare industry is not completely immune to recession, as healthcare institutions thought firings and employment during past financial downturns. That stated, the industry does cope finer than other sectors because of its essential nature. However, the danger of recession threatens the market as inflation persists increasing. The elevated extent of tension about the persistent recession as the high inflation in developed countries worldwide has transpired in a general cost surge over the past two years. The cumulatively deteriorating general purchasing control is anticipated to affect growing economies particularly and is considered helpful in numerous ways.

Segment Analysis

The global chemotherapy-induced anemia market is segmented based on disease type, treatment type, drug type, end-user, and region.

The Erythropoiesis-Stimulating Agents (ESAs) Treatment Type Segment Is Estimated To Hold A 34.1% Share Of The Global Market By 2030.

The erythropoiesis-stimulating agents (ESAs) treatment type segment is estimated to hold about 34% of the total chemotherapy-induced anemia market by 2030, owing to the increasing clinical research activities. For instance, in May 2023, FibroGen, Inc., a top biopharmaceutical enterprise committed to finding, creating, and selling a product line of first-in-class therapeutics, and its associate, FibroGen (China) Medical Technology Development Co., Ltd. informed favorable topline information from corporation's Phase 3 clinical trial of roxadustat for the treatment of anemia in people taking coexisting chemotherapy drug for non-myeloid malignancies in China.

Geographical Analysis

Europe is Estimated To Hold The Second-Largest Share Of The Global Chemotherapy-Induced Anemia Market During The Forecast Period.

Owing to the growing number of cancer dea?hs and measures to battle against cancer, Europe is estimated to hold about 26.6% of the global chemotherapy-induced anemia market by 2030. For instance, according to the 2022 edition of Health at a Glance, cancer is the second largest basis for death in the European Union following cardiovascular conditions. Over 30-50% of cancer individuals' deaths are avertable, and mortality can also be lowered via premature identification and the essential better punctual, and efficacious cures. Europe's Beating Cancer Plan aims to lower the burden of cancer and handle cancer-related inequalities among and in the governments, with struggles to aid, harmonize and satisfy the activities of Member States.

Competitive Landscape

The major global players in the market include: Dr. Reddy's Laboratories Ltd, Pfizer Inc, Panacea Biotec Limited, SBI PHARMACEUTICALS CO., LTD, Tolero Pharmaceuticals, Inc., Vifor Pharma AG, Therapure Biopharma Inc., PharmaEssentia Corp., PhytoHealth Corp, and UBI Pharma Inc among others.

Why Purchase the Report?

To visualize the global chemotherapy-induced anemia market segmentation based on disease type, treatment type, drug type, end-user, and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of chemotherapy-induced anemia market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.

The global chemotherapy-induced anemia market report would provide approximately 53 tables, 54 figures, and 195 pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Disease Type
3.2. Snippet by Treatment Type
3.3. Snippet by Drug Type
3.4. Snippet by End User
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Research Activities
  - 4.1.1.2. Growing Cancer Prevalence
- 4.1.2. Restraints
  - 4.1.2.1. Stringent Regulatory Authorities
- 4.1.3. Opportunity
- 4.1.4. Government Initiatives
- 4.1.5. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Regulatory Analysis
5.3. Pricing Analysis
5.4. Patent Analysis
5.5. PEST Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers' Strategic Initiatives
6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Global Recession Analysis

9. By Disease Type

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 9.1.2. Market Attractiveness Index, By Disease Type
9.2. Mild Anemia
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Moderate Anemia
9.4. Severe Anemia

10. By Treatment Type

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 10.1.2. Market Attractiveness Index, By Treatment Type
10.2. RBC Transfusions
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Erythropoiesis-stimulating agents (ESAs)
10.4. Iron Supplementation

11. By Drug Type

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 11.1.2. Market Attractiveness Index, By Drug Type
11.2. Epogen Injection
- 11.2.1. Introduction
- 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Procrit Injection
11.4. Androxy Oral
11.5. Aranesp injection
11.6. Epoetin Alfa Injection
11.7. Others

12. By End User

12.1. Introduction
- 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 12.1.2. Market Attractiveness Index, By End User
12.2. Hospitals
- 12.2.1. Introduction
- 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.3. Specialty Clinics
12.4. Ambulatory Surgical Centers
12.5. Cancer Research Centers
12.6. Cancer Rehabilitation Centers

13. By Region

13.1. Introduction
- 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 13.1.2. Market Attractiveness Index, By Region
13.2. North America
- 13.2.1. Introduction
- 13.2.2. Key Region-Specific Dynamics
- 13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 13.2.7.1. The U.S.
  - 13.2.7.2. Canada
  - 13.2.7.3. Mexico
13.3. Europe
- 13.3.1. Introduction
- 13.3.2. Key Region-Specific Dynamics
- 13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 13.3.7.1. Germany
  - 13.3.7.2. The U.K.
  - 13.3.7.3. France
  - 13.3.7.4. Italy
  - 13.3.7.5. Spain
  - 13.3.7.6. Rest of Europe
13.4. South America
- 13.4.1. Introduction
- 13.4.2. Key Region-Specific Dynamics
- 13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 13.4.7.1. Brazil
  - 13.4.7.2. Argentina
  - 13.4.7.3. Rest of South America
13.5. Asia-Pacific
- 13.5.1. Introduction
- 13.5.2. Key Region-Specific Dynamics
- 13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 13.5.7.1. China
  - 13.5.7.2. India
  - 13.5.7.3. Japan
  - 13.5.7.4. Australia
  - 13.5.7.5. Rest of Asia-Pacific
13.6. Middle East and Africa
- 13.6.1. Introduction
- 13.6.2. Key Region-Specific Dynamics
- 13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 13.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

14. Competitive Landscape

14.1. Competitive Scenario
14.2. Market Share Analysis
14.3. Mergers and Acquisitions Analysis

15. Company Profiles

15.1. Dr. Reddy's Laboratories Ltd.
- 15.1.1. Company Overview
- 15.1.2. Disease Type Portfolio and Description
- 15.1.3. Financial Overview
- 15.1.4. Key Developments
15.2. Pfizer Inc
15.3. Panacea Biotec Limited
15.4. SBI PHARMACEUTICALS CO., LTD
15.5. Tolero Pharmaceuticals, Inc.
15.6. Vifor Pharma AG
15.7. Therapure Biopharma Inc.
15.8. PharmaEssentia Corp.
15.9. PhytoHealth Corp
15.10. UBI Pharma Inc

LIST NOT EXHAUSTIVE

16. Appendix

16.1. About Us and Services
16.2. Contact Us

02-2025-2992
(주말 및 공휴일 제외)

라이선스 / 가격

PDF & Excel (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,350

￦ 6,173,000

PDF & Excel (Multiple User License)

PDF 보고서를 동일 사업장에서 7명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,850

￦ 6,882,000

PDF & Excel (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 7,850

￦ 11,139,000

※ 부가세 별도

세계의 화학요법 유발성 빈혈 시장(2023-2030년)

Global Chemotherapy-Induced Anemia Market - 2023-2030

시장 개요

시장 역학

고령화 인구는 세계 화학요법 유발성 빈혈 시장에 긍정적인 성장 기회를 제공하고 있습니다.

COVID-19의 영향 분석

러시아·우크라이나 분쟁의 영향 분석

세계적 불황의 영향 분석

목차

제1장 조사 방법과 범위

제2장 정의와 개요

제3장 주요 요약

제4장 시장 역학

제5장 산업 분석

제6장 COVID-19의 분석

제7장 러시아·우크라이나 전쟁 분석

제8장 세계 동시 불황 분석

제9장 질환 유형별

제10장 치료법별

제11장 약제별

제12장 최종사용자별

제13장 지역별

제14장 경쟁 구도

제15장 기업 개요

제16장 부록